A Single Radioactive Iodine Treatment Has a Deleterious Effect on Ovarian Reserve in Women with Thyroid Cancer: Results of a Prospective Pilot Study
- PMID: 29466932
- DOI: 10.1089/thy.2017.0442
A Single Radioactive Iodine Treatment Has a Deleterious Effect on Ovarian Reserve in Women with Thyroid Cancer: Results of a Prospective Pilot Study
Abstract
Background: Women of reproductive age with differentiated thyroid cancer (DTC) often need radioactive iodine (RAI) treatment after surgery. In contrast to the well-documented effect of RAI on testicular function, the potential negative effects of this treatment on ovarian reserve have been largely dismissed. The objective of this pilot study was to examine the possibility that RAI treatment is deleterious to the ovarian reserve by prospectively measuring the concentration of anti-Müllerian hormone (AMH) after RAI treatment.
Methods: Thirty premenopausal women (Mage = 34 years; range 20-45 years) with a new diagnosis of DTC scheduled to undergo RAI ablation were recruited for this study. All of them had TNM stage 1 disease (T1-3, N0, or N1, M0), and were scheduled to receive RAI activities ranging from 30 to 150 mCi. AMH was measured at baseline and at 3, 6, 9, and 12 months after the administration of RAI.
Results: Of the 30 women, only 24 returned after the baseline assessment. RAI treatment resulted in a significant decrease in AMH concentrations at three months, from 3.25 ± 2.75 to 1.9 ± 1.74 ng/mL (p < 0.0001). Only partial recovery was subsequently documented. Eighty-two percent of subjects had final values below baseline levels, such that at one year, serum AMH was still 32% lower than prior to treatment (2.36 ± 1.88 ng/mL; p < 0.005). The only two continuous variables that correlated with the extent of AMH reduction at three months were the woman's age (r = 0.51; p = 0.02) and the age at menarche (r = 0.48; p = 0.03). Importantly, the RAI dose was not associated with the extent of AMH reduction and neither were smoking or the use of birth control pills. Older subjects (≥35 years) were significantly more likely to experience a marked AMH reduction at three months (63.7 ± 18.5% vs. 33.1 ± 29.2%; p = 0.01). The only predictor of recovery after one year was the extent of AMH decrease at three months: the lower the decline, the higher the chances for recovery.
Conclusions: RAI in DTC has a rapid and profound effect on ovarian reserve, with only a partial recovery potential. In an era of declining human fertility, it is of relevance to recognize the potentially adverse effect of RAI in women of reproductive age. AMH measurement may be useful as a tool in this decision-making process.
Keywords: anti-Müllerian hormone; ionizing radiation; ovarian reserve; radioactive iodine; thyroid cancer.
Similar articles
-
Longitudinal Analysis of the Effect of Radioiodine Therapy on Ovarian Reserve in Females with Differentiated Thyroid Cancer.Thyroid. 2020 Apr;30(4):580-587. doi: 10.1089/thy.2019.0504. Epub 2020 Feb 10. Thyroid. 2020. PMID: 31928168
-
Effects of Radioactive Iodine Therapy on Ovarian Reserve: A Prospective Pilot Study.Thyroid. 2018 Dec;28(12):1702-1707. doi: 10.1089/thy.2018.0129. Epub 2018 Sep 29. Thyroid. 2018. PMID: 30156472
-
Evaluation of Ovarian Reserve with AMH Level in Patients with Well-Differentiated Thyroid Cancer Receiving Radioactive Iodine Ablation Treatment.Exp Clin Endocrinol Diabetes. 2016 Nov;124(10):593-596. doi: 10.1055/s-0042-115639. Epub 2016 Oct 6. Exp Clin Endocrinol Diabetes. 2016. PMID: 27711957
-
A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors.Clin Endocrinol (Oxf). 2008 Sep;69(3):479-90. doi: 10.1111/j.1365-2265.2008.03222.x. Epub 2008 Feb 13. Clin Endocrinol (Oxf). 2008. PMID: 18284643 Review.
-
Anti-Müllerian hormone as a predictor of reproductive potential.Curr Opin Endocrinol Diabetes Obes. 2018 Dec;25(6):385-390. doi: 10.1097/MED.0000000000000440. Curr Opin Endocrinol Diabetes Obes. 2018. PMID: 30299431 Review.
Cited by
-
Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function.J Clin Endocrinol Metab. 2020 Nov 1;105(11):3361-73. doi: 10.1210/clinem/dgaa513. J Clin Endocrinol Metab. 2020. PMID: 32770239 Free PMC article. Review.
-
Impact of Nasolacrimal Dysfunction in Thyroid Cancer Survivors.Thyroid. 2022 May;32(5):483-485. doi: 10.1089/thy.2022.0095. Epub 2022 Mar 22. Thyroid. 2022. PMID: 35180829 Free PMC article. No abstract available.
-
2021 European Thyroid Association Guideline on Thyroid Disorders prior to and during Assisted Reproduction.Eur Thyroid J. 2021 Feb;9(6):281-295. doi: 10.1159/000512790. Epub 2021 Jan 21. Eur Thyroid J. 2021. PMID: 33718252 Free PMC article.
-
Effect of actinomycin D on ovarian reserve in low-risk gestational trophoblastic neoplasia.Int J Gynecol Cancer. 2023 Aug 7;33(8):1222-1226. doi: 10.1136/ijgc-2023-004292. Int J Gynecol Cancer. 2023. PMID: 37290904 Free PMC article.
-
Assessment of different markers of ovarian reserve in women with papillary thyroid cancer treated with radioactive iodine.Endocr Connect. 2021 Oct 11;10(10):1283-1290. doi: 10.1530/EC-21-0187. Endocr Connect. 2021. PMID: 34524978 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical